Apyx Medical Corp: Form 10-K/A for the period ended Dec 31, 2013
Filed with the SEC on May 8, 2014 and accepted by EDGAR at May 8, 2014, 16:56 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Gross profit | 3 months2013-10-01 to 2013-12-31 | $2.6m | us-gaap:GrossProfit |
| Net income | 3 months2013-10-01 to 2013-12-31 | −$5.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2013-10-01 to 2013-12-31 | −$0.30 | us-gaap:EarningsPerShareDiluted |
| Operating cash flow | 12 months2013-01-01 to 2013-12-31 | −$2.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2013-01-01 to 2013-12-31 | $588.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2013-12-31 | $7.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2013-12-31 | $19.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2013-12-31 | $33.2m | us-gaap:Assets |
| Current liabilities | At period end2013-12-31 | $2.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2013-12-31 | $11.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2013-12-31 | $19.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001477932-14-002386. Last ingested by Listed: Nov 5, 2026, 13:09 ET. Listed shows no prices and gives no investment advice.